BR112022011786A2 - Composição farmacêutica de pirazol - Google Patents

Composição farmacêutica de pirazol

Info

Publication number
BR112022011786A2
BR112022011786A2 BR112022011786A BR112022011786A BR112022011786A2 BR 112022011786 A2 BR112022011786 A2 BR 112022011786A2 BR 112022011786 A BR112022011786 A BR 112022011786A BR 112022011786 A BR112022011786 A BR 112022011786A BR 112022011786 A2 BR112022011786 A2 BR 112022011786A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pyrazole
surfactant
same
atopic dermatitis
Prior art date
Application number
BR112022011786A
Other languages
English (en)
Inventor
D Brown Chad
D Kulczar Christopher
Wang Chen-Chao
H Fung Michelle
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022011786A2 publication Critical patent/BR112022011786A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA DE PIRAZOL. Uma composição farmacêutica de um composto pirazólico e um tensoativo e um método de uso dos mesmos para tratar dermatite atópica.
BR112022011786A 2019-12-20 2020-12-18 Composição farmacêutica de pirazol BR112022011786A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951185P 2019-12-20 2019-12-20
PCT/EP2020/086944 WO2021123108A1 (en) 2019-12-20 2020-12-18 A pyrazole pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR112022011786A2 true BR112022011786A2 (pt) 2022-08-30

Family

ID=74184584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011786A BR112022011786A2 (pt) 2019-12-20 2020-12-18 Composição farmacêutica de pirazol

Country Status (15)

Country Link
US (1) US20230070369A1 (pt)
EP (2) EP4282475A3 (pt)
JP (1) JP2023506921A (pt)
KR (1) KR20220119024A (pt)
CN (1) CN114845702B (pt)
AU (1) AU2020409588A1 (pt)
BR (1) BR112022011786A2 (pt)
CA (1) CA3163925A1 (pt)
DK (1) DK4076404T3 (pt)
ES (1) ES2967892T3 (pt)
FI (1) FI4076404T3 (pt)
MX (1) MX2022007581A (pt)
PL (1) PL4076404T3 (pt)
PT (1) PT4076404T (pt)
WO (1) WO2021123108A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023118555A1 (en) * 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
CA2816957A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2011336478A1 (en) * 2010-12-03 2013-06-06 Novartis Ag Pharmaceutical compositions
US9248193B2 (en) * 2011-03-18 2016-02-02 Abbvie Inc. Formulations of phenyl uracil compounds
US9328099B2 (en) 2011-09-22 2016-05-03 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2018108969A1 (en) 2016-12-14 2018-06-21 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
CN111465412A (zh) * 2017-12-21 2020-07-28 英特维特国际股份有限公司 Nk-1拮抗剂的口服药物组合物

Also Published As

Publication number Publication date
EP4076404A1 (en) 2022-10-26
MX2022007581A (es) 2022-07-19
JP2023506921A (ja) 2023-02-20
EP4076404B1 (en) 2023-11-15
EP4282475A3 (en) 2024-02-28
CN114845702B (zh) 2024-03-15
KR20220119024A (ko) 2022-08-26
AU2020409588A1 (en) 2022-06-09
US20230070369A1 (en) 2023-03-09
CA3163925A1 (en) 2021-06-24
FI4076404T3 (fi) 2024-01-31
ES2967892T3 (es) 2024-05-06
PT4076404T (pt) 2024-01-12
EP4282475A2 (en) 2023-11-29
DK4076404T3 (da) 2024-01-22
PL4076404T3 (pl) 2024-02-19
WO2021123108A1 (en) 2021-06-24
CN114845702A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
WO2019222112A8 (en) Mcl-1 inhibitors
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
UY36014A (es) ?derivado de pirazol amida, composición farmacéutica y método para tratar o prevenir enfermedades autoinmunes, inflamatorias, metabólicas o cancerosas?.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
PH12020551728A1 (en) Stat3 inhibitors
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
BR112018074718A2 (pt) composição líquida não oleosa, não aquosa, e, método de controle de nematódeos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017022281A2 (pt) métodos para tratar câncer
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
CO2022004699A2 (es) Composición mejorada
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
BR112022011786A2 (pt) Composição farmacêutica de pirazol
CL2015003433A1 (es) Derivados de tilosina y método para su preparación
MX2020009813A (es) Composiciones y metodos para tratar el prurito.
BR112016016672A2 (pt) Uso de uma composição